Examining how different ways of giving dexmedetomidine affect recovery after hip surgery
Effect of Different Administration Routes of Dexmedetomidine Combined with Ultrasound-Guided Fascia Iliaca Block on Emergence Agitation After Hip Replacement Surgery
PHASE1 · Qianfoshan Hospital · NCT06614010
This study is testing different ways to give a medication called dexmedetomidine to see if it helps people aged 18 to 65 recover better and feel less agitated after hip replacement surgery.
Quick facts
| Phase | PHASE1 |
|---|---|
| Study type | Interventional |
| Enrollment | 207 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Qianfoshan Hospital (other) |
| Locations | 1 site (Jinan, Shandong) |
| Trial ID | NCT06614010 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of various administration routes of dexmedetomidine combined with ultrasound-guided fascia iliaca block on emergence agitation in patients recovering from hip replacement surgery. It aims to determine the optimal method for administering dexmedetomidine to enhance postoperative recovery and minimize agitation. The study will involve patients aged 18 to 65 who are undergoing hip arthroplasty and meet specific health criteria. Participants will receive different combinations of dexmedetomidine and ropivacaine to assess their effectiveness in reducing agitation during recovery.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 65 with hip joint disease requiring surgery and no significant health issues.
Not a fit: Patients with allergies to study medications, severe nervous system disorders, or those unable to cooperate with the study may not benefit.
Why it matters
Potential benefit: If successful, this study could lead to improved recovery experiences for patients undergoing hip replacement surgery by reducing postoperative agitation.
How similar studies have performed: While similar approaches have been explored, this specific combination of dexmedetomidine and fascia iliaca block is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. age between 18 and 65 years, with no restriction on gender 2. diagnosis of hip joint disease necessitating hip arthroplasty 3. ASA grade I-II 4. no significant cardiopulmonary, hepatic, or renal dysfunction prior to the operation 5. no history of psychiatric disorders or long-term use of sedative medications prior to the operation 6. signing of an informed consent form to voluntarily participate in the study. Exclusion Criteria: 1. patients allergic to or with contraindications to ropivacaine or dexmedetomidine 2. patients exhibiting symptoms of agitation or delirium prior to the procedure 3. patients with severe central or peripheral nervous system disorders 4. patients with coagulation disorders or receiving anticoagulant therapy 5. pregnant or breastfeeding women 6. patients who received other medications or treatments prior to the procedure that might affect the study results 7. patients unable to cooperate with the study or intolerant to ultrasound-guided iliofascial block
Where this trial is running
Jinan, Shandong
- Qianfoshan Hospital — Jinan, Shandong, China (RECRUITING)
Study contacts
- Study coordinator: Pengcai Shi, Chief physician
- Email: shipc1997@163.com
- Phone: 13791126828
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Dexmedetomidine, Fascia Iliaca Block, Emergence Agitation, Ropivacaine, Analgesic Mechanism